KPTI (Karyopharm Therapeutics Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by KPTI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Kristin Abate | Chief Accounting Officer | Sell | — | — |
| 2026-07-30 | Stuart Poulton | EVP, Chief Development Officer | Sell | — | — |
| 2026-05-26 | GAREN G BOHLIN | Director | A | — | — |
| 2026-05-26 | Christy J. Oliger | Director | A | — | — |
| 2026-05-26 | DEEPIKA PAKIANATHAN | Director | A | — | — |
| 2026-05-26 | Chen Schor | Director | A | — | — |
| 2026-05-26 | Barry E Greene | Director | A | — | — |
| 2026-05-26 | Zhen Su | Director | A | — | — |
| 2026-05-15 | Michael Mano | EVP, CLO&Secretary | MIXED | — | — |
| 2026-05-15 | Kristin Abate | Chief Accounting Officer | MIXED | — | — |
| 2026-05-15 | Stuart Poulton | EVP, Chief Development Officer | MIXED | — | — |
| 2026-05-15 | Sohanya Roshan Cheng | EVP & Chief Commercial Officer | MIXED | — | — |
| 2026-05-15 | Reshma Rangwala | EVP & Chief Medical Officer | MIXED | — | — |
| 2026-05-15 | Richard A. Paulson | President and CEO | MIXED | — | — |
| 2026-04-22 | Reshma Rangwala | EVP & Chief Medical Officer | Sell | — | — |
| 2026-03-03 | Kristin Abate | Chief Accounting Officer | Sell | — | — |
| 2026-03-03 | Richard A. Paulson | President and CEO | Sell | — | — |
| 2026-03-03 | Reshma Rangwala | EVP & Chief Medical Officer | Sell | — | — |
| 2026-03-03 | Stuart Poulton | EVP, Chief Development Officer | Sell | — | — |
| 2026-03-03 | Sohanya Roshan Cheng | EVP & Chief Commercial Officer | Sell | — | — |
| 2026-03-03 | Michael Mano | EVP, CLO&Secretary | Sell | — | — |
| 2026-02-19 | Stuart Poulton | EVP, Chief Development Officer | Sell | — | — |
| 2026-02-09 | Richard A. Paulson | President and CEO | A | — | — |
| 2026-02-04 | Lori Macomber | EVP, CFO & Treasurer | Sell | — | — |
| 2026-02-03 | Stuart Poulton | EVP, Chief Development Officer | A | — | — |
| 2026-02-03 | Sohanya Roshan Cheng | EVP & Chief Commercial Officer | A | — | — |
| 2026-02-03 | Michael Mano | EVP, CLO&Secretary | A | — | — |
| 2026-02-03 | Reshma Rangwala | EVP & Chief Medical Officer | A | — | — |
| 2026-02-03 | Lori Macomber | EVP, CFO & Treasurer | A | — | — |
| 2026-01-29 | Kristin Abate | Chief Accounting Officer | MIXED | — | — |
| 2026-01-22 | Kristin Abate | Chief Accounting Officer | Sell | — | — |
| 2025-10-16 | Stuart Poulton | EVP, Chief Development Officer | A | — | — |
| 2025-10-16 | Sohanya Roshan Cheng | EVP & Chief Commercial Officer | A | — | — |
| 2025-10-16 | Michael Mano | SVP, General Counsel&Secretary | A | — | — |
| 2025-10-16 | Kristin Abate | Chief Accounting Officer | A | — | — |
| 2025-10-16 | Richard A. Paulson | President and CEO | A | — | — |
| 2025-10-16 | Lori Macomber | EVP, CFO & Treasurer | A | — | — |
| 2025-10-03 | Kristin Abate | Chief Accounting Officer | Sell | — | — |
| 2025-09-16 | Reshma Rangwala | EVP & Chief Medical Officer | MIXED | — | — |
| 2025-09-16 | Sohanya Roshan Cheng | EVP & Chief Commercial Officer | MIXED | — | — |
| 2025-09-16 | Kristin Abate | Chief Accounting Officer | MIXED | — | — |
| 2025-09-16 | Richard A. Paulson | President and CEO | MIXED | — | — |
| 2025-09-16 | Stuart Poulton | EVP, Chief Development Officer | MIXED | — | — |
| 2025-09-16 | Michael Mano | SVP, General Counsel&Secretary | MIXED | — | — |
| 2025-09-04 | Kristin Abate | Chief Accounting Officer | Sell | — | — |
| 2025-07-30 | Stuart Poulton | EVP, Chief Development Officer | Sell | — | — |
| 2025-07-23 | Kristin Abate | Chief Accounting Officer | Sell | — | — |
| 2025-05-29 | Zhen Su | Director | A | — | — |
| 2025-05-29 | Chen Schor | Director | A | — | — |
| 2025-05-29 | Christy J. Oliger | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 842,645 | — |
| — | 10%+ Owner | 729,038 | — |
| — | 10%+ Owner | 593,368 | — |
| — | 10%+ Owner | 555,502 | — |
| — | 10%+ Owner | 522,404 | — |
| — | 10%+ Owner | 508,751 | — |
| — | President and CEO | 269,747 | — |
| — | Chief Scientific Officer | 111,459 | — |
| — | EVP & Chief Commercial Officer | 108,264 | — |
| — | Chief Executive Officer | 107,874 | — |
| — | EVP, Chief Development Officer | 94,632 | — |
| — | EVP, CLO&Secretary | 94,398 | — |
| — | EVP, CFO & Treasurer | 85,105 | — |
| — | EVP & Chief Medical Officer | 56,829 | — |
| — | Director | 30,795 | — |
| — | EVP, CFO & Treasurer | 26,070 | — |
| — | Chief Accounting Officer | 23,782 | — |
| — | Director | 18,517 | — |
| — | Director | 16,415 | — |
| — | Director | 15,508 | — |
| — | Director | 15,508 | — |
| — | Director | 15,508 | — |
| — | EVP, Chief Dev. Officer | 11,330 | — |
| — | EVP, Chief Medical Officer | 8,630 | — |
| — | SVP, Chief Business Officer | 8,554 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KPTI quote page; the site-wide leaderboard is on the insider transactions hub.